Aerpio Pharmaceuticals posted a net loss of $6 million, or $0.22 per share, in the second quarter of 2018, compared to a net loss of $5.5 million, or $0.21 per share, in the same period of 2017.
General and administrative expenses for the quarter increased 30%, or $0.7 million, while research and development costs went up 33%, or $1.1 million.
The company had cash and cash equivalents of $68.8 million as of June 30, 2018.
Uncategorized